HEREDITARY MULTIPLE MYELOMA

Multiple Myeloma Hereditary Risk — first-degree relatives have 2-4x increased risk, and genetic profiling of MGUS patients may help predict which individuals will progress to myeloma requiring treatment.

Whole genome sequencing evaluates all known myeloma susceptibility loci and germline variants — providing genetic risk assessment that may guide MGUS surveillance intensity and early myeloma detection strategies.

About this condition

Multiple Myeloma — Hereditary

Multiple myeloma is a plasma cell malignancy affecting approximately 35,000 Americans annually. While most myeloma is sporadic, epidemiological studies consistently demonstrate familial clustering — first-degree relatives of myeloma patients have approximately 2-4x increased risk of developing myeloma and other lymphoproliferative disorders. Genome-wide association studies have identified multiple susceptibility loci including variants at 2p23.3, 3p22.1, 3q26.2, 6p21.33 (HLA region), 7p15.3, and 17p11.2, each conferring modest individual risk increases that compound in polygenic risk scores.

Monoclonal gammopathy of undetermined significance (MGUS) precedes virtually all myeloma cases, with approximately 1% of MGUS progressing to myeloma per year. The clinical challenge is identifying which MGUS patients will progress. Genetic risk profiling — combining germline susceptibility variants with MGUS-specific risk factors (M-protein level, immunoglobulin subtype, free light chain ratio) — represents an emerging approach to risk-stratified MGUS surveillance that could enable earlier myeloma detection at more treatable stages.

Familial myeloma kindreds have been described with multiple affected family members across generations, suggesting higher-penetrance germline variants in a subset of cases. Candidate genes under investigation include KDM1A, LSD1, and variants in DNA damage response pathways. Additionally, germline variants affecting immune function and B-cell biology may predispose to the immune dysregulation underlying MGUS and myeloma development. Comprehensive genomic evaluation through WGS enables ongoing reanalysis as myeloma genetics research matures.

MGUS precedes virtually all myeloma — it's the premalignant phase. Identifying individuals at highest genetic risk for MGUS progression could enable earlier myeloma detection when treatment is most effective.

Gene locus: Multiple GWAS loci: 2p23.3, 3p22.1, 3q26.2, 6p21.33, 7p15.3, 17p11.2

Myeloma genetics is an actively evolving field. WGS provides a permanent genomic resource for ongoing reanalysis as new myeloma susceptibility genes and progression biomarkers are discovered.

First-degree relatives of myeloma patients have 2-4x increased risk — genetic evaluation supports risk-stratified screening

Family members of myeloma patients are at significantly elevated risk for both MGUS and myeloma. Serum protein electrophoresis (SPEP) screening can detect MGUS before myeloma develops. Genetic risk profiling through WGS can help identify which family members would benefit most from regular SPEP screening — focusing surveillance resources on those with the highest genetic predisposition.

Polygenic risk scores for myeloma are improving — WGS captures all known and emerging susceptibility variants

As myeloma GWAS studies expand and new susceptibility loci are discovered, polygenic risk scores will become increasingly predictive. WGS data captured today can be reanalyzed against future risk score models without requiring additional testing. This 'test once, analyze forever' approach is particularly valuable for evolving cancer genetics fields like myeloma.

Multiple Myeloma Hereditary Risk — first-degree relatives have 2-4x increased risk, and genetic profiling of MGUS patients may help predict which individuals will progress to myeloma requiring treatment.